Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties

Psychopharmacology

Volumn 182, Issue 3, 2005, Pages 400-413

  Artaiz, Inés ^a   Zazpe, Arturo ^a   Innerárity, Ana ^a   Del Olmo, Elena ^a   Díaz, Alvaro ^b   Ruiz Ortega, José Angel ^b,c   Castro, Elena ^b   Pena, Ruth ^a,b   Labeaga, Luis ^a   Pazos, Angel ^b   Orjales, Aurelio ^a  

^a S A ^*  (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Animal model; Antidepressant; Anxiolytic; Norepinephrine; Serotonin; Uptake inhibitor

Indexed keywords

1 METHYL 3 INDAZOLECARBOXYLIC ACID N TROPANYLAMIDE; 1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; 2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 5 HYDROXYTRYPTOPHAN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ASTEMIZOLE; ATROPINE; DESIPRAMINE; F 98214TA; FLUOXETINE; IMIPRAMINE; KETANSERIN; MEPYRAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 3 METHYL 4 (4 PYRIDYL)BENZAMIDE; NISOXETINE; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PIPERIDINE DERIVATIVE; PRAZOSIN; RACLOPRIDE; S 4 [(3 FLUOROPHENOXY)PHENYL]METHYLPIPERIDINE; SEROTONIN 1A ANTAGONIST; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; FORCED SWIMMING TEST; GUINEA PIG; HYPERACTIVITY; HYPOTHERMIA; MALE; MOUSE; NERVE CELL; NEUROCHEMISTRY; NEUROPHARMACOLOGY; NONHUMAN; OLFACTORY BULBECTOMY; PHARMACODYNAMICS; PHARMACOLOGICAL BLOCKING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SOCIAL INTERACTION; SYNAPTOSOME; TRANQUILIZING ACTIVITY;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; APOMORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; MALE; MICE; MOTOR ACTIVITY; NOREPINEPHRINE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 26844489742     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0087-3     Document Type: Article

References (81)

1. Aghajanian GK (1978) Feedback regulation of central monoaminergic neurons: evidence from single cell recording studies. In: Youdin MBH, Lovenberg W, Sharman DF, Lagnado JR (eds) Essays in neurochemistry and neuropharmacology. Wiley, New York, pp 1-32
2. Anderson IM (1998) SSRIs versus tricyclic antidepressants in depressed impatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7:11-17
3. Anderson IM (2001) Meta-analytical studies on new antidepressants. Br Med Bull 57:161-178
4. Béique JC, De Montigny C, Blier P, Debonnel G (1999) Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse 32:198-211
5. Bel N, Artigas F (1999) Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran. Neuropsychopharmacology 21:745-754
6. 1 receptors in the rodent. Arzneim Forsch 45:551-558
7. Bjorvatn B, Fornal CA, Martín FJ, Metzler CW, Jacobs BL (2000) Venlafaxine and its interaction with WAY100,635: effects on serotonergic unit activity and behaviour in cats. Eur J Pharmacol 404:121-132
8. Borsini F (1995) Role of the serotonergic system in the forced swimming test. Neurosci Biobehav Rev 19:377-395
9. Borsini F, Meli A (1988) Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 94:147-160
10. Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology 163:121-141
11. Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ (2002) Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. Pharmacol Biochem Behav 71:667-680
12. Brunello N, Racagni G (1998) Rationale for the development of noradrenaline reuptake inhibitors. Hum Psychopharmacol 13:S13-S19
13. Burnett FE, Dinan TG (1998) Venlafaxine. Pharmacology and therapeutic potential in the treatment of depression. Hum Psychopharmacol 13:153-162
14. Buus Lassen J (1978) Potent and long-lasting potentiation of two 5-hydroxytryptophan-induced effects in mice by three selective 5-HT uptake inhibitors. Eur J Pharmacol 47:351-358
15. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871-880
16. Bymaster FP, McNamara RK, Tran PV (2003) New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Expert Opin Investig Drugs 12:531-543
17. Cairncross KD, Cox B, Forster C, Wren AF (1978) A new model for the detection of antidepressant drugs: olfactory bulbectomy in the rat compared with existing models. J Pharmacol Methods 1:131-143
18. Cervo L, Grignaschi G, Rossi C, Samanin R (1991) Role of serotonergic neurons in the effect of sertraline in rats in the forced swimming test. Eur J Pharmacol 196:217-222
19. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
20. Clerc G, Milnacipran/Fluvoxamine Study Group (2001) Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol 16:145-151
21. Cryan JF, Mc Grath C, Leonard BE, Norman TR (1998) Combining pindolol and paroxetine in an animal model of chronic antidepressant action. Can early onset of action be detected? Eur J Pharmacol 352:23-28
22. Czachura JF, Rasmussen K (2000) Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal rapphe nucleus of the rat. Naunyn-Schmiedeberg's Arch Pharmacol 362:266-275
23. Dalvi A, Lucid I (1999) Murine models of depression. Psychopharmacology 147:14-16
24. David DJP, Renard CE, Jolliet P, Hascoët M, Bourin M (2003) Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology 166:373-382
25. de Oliveira RA, Cunha GM, Borges KD, de Bruin GS, dos Santos-Filho EA, Viana GS, de Bruin VM (2004) The effect of venlafaxine on behaviour, body weight and striatal monoamine levels on sleep-deprived female rats. Pharmacol Biochem Behav 79:499-506
26. Dekeyne A, Denorme B, Monneyron S, Millan MJ (2000) Citalopram reduces social interaction in rats by activation of serotonin (5-HT) (2C) receptors. Neuropharmacology 39:1114-1117
27. Detke MJ, Rickels M, Lucid I (1995) Active behaviours in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121:66-72
28. 1D/1B receptor antagonist. Naunyn-Schmiedeberg's Arch Pharmacol 356:328-334
29. 1A receptor antagonist WAY100635. Brit J Pharmacol 130:1713-1719
30. Entsuah R, Derivan A, Kikta D (1998) Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients. Clin Ther 20:517-526
31. 3H]- Rauwolscine? A comparison of nine tissues and cell lines. J Pharmacol Exp Ther 273:1287-1294
32. 1A receptor modulation of anxiety in two ethological animal tests. J Neurosci 16:4810-4815
33. Fuxe K, Sjöqvist F (1972) Hypothermic effect of apomorphine in the mouse. J Pharm Pharmacol 24:702-705
34. Goldstein BJ, Goodnick PJ (1998) Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 12:855-S87
35. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA (2004) Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 24:389-399
36. Goodnick PJ, Goldstein BJ (1998) Selective serotonin reuptake inhibitors in the treatment of affective disorders-II. Efficacy and quality of life. J Psychopharmacol 12:S21-S54
37. 1 dopamine receptors in rat striatum. Eur J Pharmacol 121:31-38
38. Hindmarch I (2001) Expanding the horizons of depression: beyond the monoamine hypothesis. Hum Psychopharmacol Clin Exp 16:203-218
39. Hughes ZA, Stanford SC (1998) Evidence from microdialysis and synaptosomal studies of rat cortex for noradrenaline uptake sites with different sensitivities to SSRIs. Br J Pharmacol 124:1141-1148
40. Kelly JP, Wrynn AS, Leonard BE (1997) The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74:299-316
41. Kent JM, Coplan JD, Gorman JM (1998) Clinical utility of the selective reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry 44:812-824
42. Kerrigan F (1998) Antidepressant patents: 1995-1997. Expert Opin Ther Pat 8:439-460
43. Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, Nelson DL, Perry KW, Bymaster FP (2003) Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45:935-944
44. Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99-113
45. Lucki I, Singh A, Kreiss DS (1994) Antidepressant-like behavioural effects of serotonin receptor agonists. Neurosci Biobehav Rev 18:85-95
46. McGrath C, Norman TR (1998) The effect of venlafaxine treatment on the neurochemical changes in the olfactory bulbectomised rat. Psychopharmacology 136:394-401
47. Millan MJ (2004) The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur J Pharmacol 500:371-384
48. Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet JM, Auclair A, Peglion JL (2001a) S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298:565-580
49. Millan MJ, Dekeyne A, Papp M, La Rochelle CD, MacSweeny C, Peglion JL, Brocco M (2001b) S33005, a novel ligand at both serotonin and norepinephrine transporters: II. behavioural profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298:581-591
50. Mochizuki D, Tsujita R, Yamada S, Kawasaki K, Otsuka Y, Hashimoto S, Hattori T, Kitamura Y, Miki N (2002) Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology 162:323-332
51. Montgomery SA (1995) Rapid onset of action of venlafaxine. Int Clin Psychopharmacol 10:21-27
52. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM (1991) Biochemical, neurophysiological, and behavioural effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 23:191-199
53. Nelson JC, Mazure CM, Bowers MB, Jatlow PI (1991) A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of depression. Arch Gen Psychiatry 48:303-307
54. Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH (2004) Combining norepinephrine and serotonin reuptake inhibition mechanism for treatment of depression: a double-blind, randomized study. Biol Psychiatry 55:296-300
55. Nielsen DM, Carey GL, Gold LH (2004) Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. Eur J Pharmacol 499:135-146
56. 3 receptor affinity of new quinolinecarboxylic acid derivatives. Drug Des Discov 16:271-279
57. Orjales A, Mosquera R, Toledo A, Pumar MC, García N, Cortizo L, Labeaga L, Innerarity A (2003) Syntheses and binding studies of new [(aryl)(aryloxy)methyl] piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters. J Med Chem 46:5512-5532
58. 3H]-prazosin in the rat cerebral cortex. Br J Pharmacol 104:961-965
59. Overstreet DH (1993) The Flinders sensitive line rats: a genetic animal model of depression. Neurosci Biobehav Rev 17:51-68
60. Owens MJ, Morga WN, Plott SJ, Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305-1322
61. Popik P, Vetulani J (1993) Similar action of imipramine and arginine-vasopressin in the social interaction test. Pol J Pharmacol 45:323-325
62. Porsolt R, Bertin A, Jalfre M (1978a) Behavioural despair in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 51:291-294
63. Porsolt R, Anton G, Blavet N, Jalfre M (1978b) Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379-391
64. Redmond AM, Kelly JP, Leonard BE (1999) The determination of the optimal dose of milnacipran in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav 62:619-623
65. Redrobe JP, Bourin M, Colombel MC, Baker GB (1998) Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology 138:1-8
66. Rénéric JP, Lucki I (1998) Antidepressant behavioural effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology 136:190-197
67. Rickels K, Pollack MH, Sheehan DV, Haskins JT (2000) Efficacy of extended-release venlafaxine in non-depressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968-974
68. Ripoll N, David DJP, Dailly E, Hascoët M, Bourin M (2003) Antidepressant-like effects in various mice strains in the tail suspension test. Behav Brain Res 143:193-200
69. Rogóz Z, Dziedzicka-Wasylewska M, Maj J (1998) The pharmacological profile of venlafaxine, a new antidepressant, given acutely. Pol J Pharmacol 50:107-115
70. Saiz-Ruiz J, Ibanez A, Díaz-Marsa M, Arias F, Padin J, Martin-Carrasco M, Montes JM, Ferrando L, Carrasco JL, Martin-Ballesteros E, Jorda L, Chamorro L (2002) Efficacy of venlafaxine in major depresion resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 26:1129-1134
71. Sanchez C, Meier E (1997) Behavioural profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology 129:197-205
72. Stenger A, Couzinier J-P, Briley M (1987) Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-amino-carbonyl-2-aminomethylcyclopropane hydrochloride (F 2207), a new potential antidepressant. Psychopharmacology 91:147-153
73. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:367-370
74. Thase ME (1998) Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 59:502-508
75. Thase ME, Entsuah AR, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241
76. Tran PV, Bymaster FP, McNamara RK, Potter WZ (2003) Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 23:78-86
77. Van Der Heyden JAM, Molewijk E, Olivier B (1987) Strain differences in response to drugs in the tail suspension test for antidepressant activity. Psychopharmacology 92:127-130
78. 3H]-Quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites: characterization and regulation of antagonist binding to putative muscarinic subtypes. J Pharmacol Exp Ther 237:419-427
79. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K (1989) Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 50:447-449
80. Wong ML, Licinio J (2001) Research and treatment approaches to depression. Nat Rev Neurosci 2:343-351
81. Zajecka JM, Albano D (2004) SNRIs in the management of acute major depressive disorder. J Clin Psychiatry 65:11-18